Four-year recurrence-free survival in metastatic uterine adenosarcoma with somatic BRCA2 mutation on olaparib therapy: A case report

Four-year recurrence-free survival in metastatic uterine adenosarcoma with somatic BRCA2 mutation on olaparib therapy: A case report

Saved in:

Bibliographic Details
Main Authors:	Katie Foug, Stephanie L. Skala, Erica Stein, Kevin Reynolds, Jean Siedel, Shitanshu Uppal
Format:	Article
Language:	English
Published:	Elsevier 2025-04-01
Series:	Gynecologic Oncology Reports
Subjects:	PARP inhibitor Uterine adenosarcoma Somatic BRCA mutation Recurrent disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352578925000499
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Uterine Adenomyosarcoma Complicated by Uterine Prolapse and Necrosis: A Case Report
by: Chang J, et al.
Published: (2025-01-01)

Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience
by: Aakriti Aggarwal, et al.
Published: (2024-09-01)

Hereditary breast and ovarian cancer syndrome (BRCA) gene: Concept, pathways, therapeutics, and future
by: Anup Tamhankar, et al.
Published: (2020-01-01)

A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
by: О. N. Churuksaeva, et al.
Published: (2023-09-01)

Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review
by: K. V. Menshikov, et al.
Published: (2022-06-01)

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
by: Anna D. Staniszewska, et al.
Published: (2022-12-01)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
by: Marta Castroviejo‐Bermejo, et al.
Published: (2018-10-01)

Ivosidenib Confers BRCAness Phenotype and Synthetic Lethality to Poly (ADP-Ribose) Polymerase Inhibition in <i>BRCA1/2</i>-Proficient Cancer Cells
by: Danyang Zhou, et al.
Published: (2025-04-01)

Overview of Roles of Novel Components in the Regulation of DNA Damage Repair in BRCA1-Deficient Cancers: An Update
by: Nhat Nguyen, et al.
Published: (2025-04-01)

The efficacy of olaparib as salvage therapy in an advanced intrahepatic cholangiocarcinoma patient harboring somatic BRCA1 and PALB2 pathogenic variants: a case report and literature review
by: Jian Wang, et al.
Published: (2025-08-01)

Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors
by: Romain Pacaud, et al.
Published: (2025-01-01)

A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer
by: A. B. Villert, et al.
Published: (2022-09-01)

Prophylactic adnexectomy in BRCA1 and BRCA2 gene mutation carriers (а review of literature)
by: T. A. Shendrikova, et al.
Published: (2014-07-01)

Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management
by: Yeon Hee Park, et al.
Published: (2025-06-01)

First‐In‐Human Dose Finding Study of Venadaparib (IDX‐1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors
by: Sung‐Bae Kim, et al.
Published: (2025-02-01)

Study of the Carrier State for Five BRCA1/BRCA2 Deleterious Mutations in Bulgarian Women with Breast Cancer
by: Katia Kovacheva, et al.
Published: (2013-12-01)

Druggable Molecular Networks in <i>BRCA1/BRCA2</i>-Mutated Breast Cancer
by: Francesca Pia Carbone, et al.
Published: (2025-03-01)

Role of BRCA 1 и BRCA 2 gene mutations in the occurrence of male breast cancer
by: A. V. Bykova, et al.
Published: (2014-07-01)

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
by: Li‐Min Wang, et al.
Published: (2023-01-01)

BRCA1, BRCA2 mutations — future of predictive oncology: a review of literature
by: V. N. Dmitriev, et al.
Published: (2014-07-01)

Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer
by: V. N. Zhurman, et al.
Published: (2023-02-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
by: Eliana MC Tacconi, et al.
Published: (2017-07-01)

Regional Differences in the Frequency of BRCA1 and BRCA2 Variants in Northeastern Japan: A Cohort Study
by: Hidekazu Shirota, et al.
Published: (2025-04-01)

Occurrence of BRCA1 and BRCA2 mutation in pancreatic cancer patients
by: A. A. Kashintsev, et al.
Published: (2016-02-01)

LOSS OF HETEROZYGOSITY IN THE BRCA1 AND BRCA2 LOCUS IN BREAST CANCER
by: M. M. Tsyganov, et al.
Published: (2020-07-01)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
by: Theresa L. Werner, et al.
Published: (2018-06-01)

A systematic review on the association between ovarian and prostate cancer with <I>BRCA1</I> and <I>BRCA2</I> gene
by: Sarpparajan Chitra Veena, et al.
Published: (2023-01-01)

Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States
by: Chenxia Xu, et al.
Published: (2025-04-01)

Hereditary breast cancer and ovarian cancer: clinical course and treatment
by: V. V. Semiglazov, et al.
Published: (2021-03-01)

Association between single nucleotide polymorphisms of DNA repair genes (BRCA1, BRCA2, and PALB2) and breast cancer incidence in a subset of Iranian population
by: Sepideh Jahangiri, et al.
Published: (2025-03-01)

Role of Single Nucleotide Polymorphisms in BRCA1 and BRCA2 Genes Relative to Previous Studies in Pakistan in the Prognosis of Breast Cancer
by: Saba Munir, et al.
Published: (2024-10-01)

Case Report: BRCA1 and BRCA2 loss in a young man with primary cutaneous extraskeletal osteosarcoma
by: Wen-Feng Luo, et al.
Published: (2025-03-01)

Distribution of age at natural menopause, age at menarche, menstrual cycle length, height and BMI in BRCA1 and BRCA2 pathogenic variant carriers and non-carriers: results from EMBRACE
by: Nasim Mavaddat, et al.
Published: (2025-05-01)

Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers
by: Anna Sokolenko, et al.
Published: (2025-06-01)

Causative Genes of Homologous Recombination Deficiency (HRD)-Related Breast Cancer and Specific Strategies at Present
by: Seigo Nakamura, et al.
Published: (2025-02-01)

HEREDITARY BREAST CANCER
by: E. M. Bit-Sava, et al.
Published: (2016-02-01)

High-Risk Factors and Therapeutic Advances in Ovarian Cancer
by: Xiaoyu SHA, et al.
Published: (2025-07-01)

Case Report: Clinical impact of BRCA1 and BRIP1 vs. BRCA1 and BRCA2 germline double heterozygosity in ovarian cancer: a comparative case study
by: Limei Zheng, et al.
Published: (2025-07-01)

BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer
by: Heidelinde Fiegl, et al.
Published: (2024-11-01)

Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients
by: Maria Delgado-Ortet, et al.
Published: (2025-06-01)